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Abstract
Hypothyroidism refers to the common pathological disorder of thyroid hormone 
deficiency. The successful therapy for hypothyroidism is levothyroxine (LT4) 
administration, which is the same as thyroxine but produced synthetically. Serum 
thyrotropin (TSH) normalization with LT4 replacement therapy in hypothyroidism 
is generally needed to restore a euthyroid state. The daily dose of thyroxine therapy 
depends on various factors, such as body weight, age, and severity. It also differs 
from hypothyroidism during pregnancy to congenital hypothyroidism. The pres-
ence of various comorbidities may exist such as myxoedema coma, coronary artery 
disease, obesity, anemia and COVID-19 which necessitate individualized treatment. 
LT4 intolerance manifested with sympathetic hyperactivity may appear during the 
first hours after the LT4 administration. It requires starting with very low doses of 
LT4 that should be increased gradually, and reaching normal TSH may take several 
months. The sympathetic hyperactivity may be attributable to the presence of 
uncorrected iron-deficiency anemia that worsens by the use of thyroid hormone.
Keywords: Levothyroxine, dose, hypothyroidism, anemia, myxoedema coma, 
treatement
1. Introduction
Hypothyroidism refers to the common disorder of thyroid hormone deficiency. 
According to the time of onset, it may be present at birth (congenital) or develop 
later in life (acquired). Treatment of hypothyroidism consists of replacing the 
deficiency of thyroid hormone to improve symptoms and prevent the adverse con-
sequences of hypothyroidism. Levothyroxine (LT4) that is identical to thyroxine but 
synthetically produced, is the most effective way to treat hypothyroidism. Treating 
hypothyroidism strategies are based on adopting an adequate dose of LT4, selecting 
a patient-appropriate serum thyrotropin (TSH) goal, and ensuring maintenance of 
that desired goal [1, 2]. The serum TSH normalization with LT4 replacement is gen-
erally needed to restore a euthyroid state. The daily LT4 dose must be individualized 
taking into account various factors such as body weight, age and severity of disease. 
Special situations may be coexisting requiring special treatement [2]. The purpose 
of this chapter is to provide the different therapeutic strategies of hypothyroidism 
management in various circumstances.
2. Congenital hypothyroidism
The guidelines of the American Academy of Pediatrics [3] and the European 
Society of Pediatric Endocrinology [4] recommends keeping TSH values below 5 
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μU/dl (optimally 0.5–2.0 μU/dl) for the first 3 years of life. LT4 is the treatment 
for hypothyroidism in children. Infants with suspected hypothyroidism require 
rapid evaluation and treatment, ideally within the first 2 weeks of life since delays 
in treatment of congenital hypothyroidism are correlated with poorer outcomes. 
Congenital hypothyroidism treatment should be initiated with 10–15 lg/kg of 
LT4 daily. Early starting treatment and adequate LT4 initial doses are associated 
with rapid normalization of thyroid function and improved neurodevelopmental 
outcomes [5].
Tablets might be crushed, suspended in a small amount of water, breast milk, or 
non–soy-based formula, and administered orally via a syringe. LT4 should not be 
administered with substances that may interfere with its absorption such as mul-
tivitamins containing calcium or iron, aluminum hydroxide and soy formula. The 
medication is administered once a day. The same dose should be repeated if there is 
immediate vomiting. If a dose is missed, it may be doubled the following day [6].
Serum thyroid function testing should be checked every 1–2 weeks until normal, 
and then every 1–2 months during the first year of life and every 2–4 months during 
the 2nd and 3rd years of life with an appropriate adjustment of LT4 dose [7]. The 
needed dose of LT4 to restore euthyroidism varied with the age and the hypothy-
roidism severity. The dose required per kilogram body mass to fully replace thyroid 
function is significantly higher in children than in adults and decreases with age 
(Table 1). Early and adequate prenatal treatment with LT4 prevents severe neuro-
cognitive deficits and results in normal brain development [1].
3. Acquired hypothyroidism
The approach to treat acquired hypothyroidism is similar to that of congenital, 
consisting of replacing the deficiency of thyroid hormones to improve symptoms 
and prevent the adverse consequences of hypothyroidism. The target is to keep 
serum TSH <5 mIU/L (optimally 0.5–2 mIU/L) [8].
The recommended treatment is LT4 in tablets form administered once daily. 
Adherence to LT4 may be influenced by multiple factors such as the time of day 
when the medication is administered. Although the majority of experts recommend 
administration of LT4 prior to food consumption, but bedtime administration may 
be more convenient and does not appear to be associated with worse control of 
hypothyroidism in children and adolescents [9].
The dose of LT4 required to restore euthyroidism depends on patient age, 
body surface area, weight and severity of hypothyroidism (Table 1) [1]. The dose 
required to fully replace thyroid function is significantly higher in children than in 







Modified from reference [1].
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adults and decreases with age. Thyroid function should be controlled 6 to 8 weeks 
after initiating therapy and then every 4 to 6 months until the child achieves final 
height or every 6 to 8 weeks following a change in LT4 dose [10].
4. Subclinical hypothyroidism
Subclinical hypothyroidism (SCH) is considered in two categories according 
to the elevation in serum TSH level: mildly increased TSH levels (4.0–10.0 mU/l), 
and more severely increased TSH value (>10 mU/l) [11]. For the American 
Thyroid Association recommendation, the goal of therapy is to normalize TSH 
levels within 0.5–3.5 mIU/L. The starting thyroid hormone treatment is recom-
mended when the serum TSH is above 10 mIU/L. The treatment is generally not 
recommended when the TSH is 5–10 mIU/L except in patients with increased 
cardiovascular risk.
These guidelines suggest that LT4 is the treatment of choice with a daily dose 
of 25–75 mcg, depending on the degree of TSH elevation and to be adjusted based 
on clinical response and serum thyroid function test monitoring. Addition with 
liothyronine (T3) is not routinely recommended [1, 12].
For the European Thyroid Association, even in the absence of symptoms, 
replacement therapy with LT4 is recommended for younger patients (<65–
70 years) who have serum TSH levels greater than 10 mIU/L and in younger SCH 
patients (serum TSH <10 mU/l) with symptoms suggestive of hypothyroidism. For 
older individuals (>80–85 years) with elevated serum TSH ≤ 10 mU/l, observa-
tion without hormonal treatment should be the strategy of choice. The aim is to 
reach a stable serum TSH in the lower half of the reference range (0.4–2.5 mU/l). 
A daily dose of LT4 between 50 and 100 μg for most SCH patients and between 
25 and 50 mcg for those with cardiac disease and/or older age has been advised to 
normalize serum TSH. The use of T3 or combined LT4/T3 is no supported in the 
treatment [11].
According to the Latin American Thyroid Society, LT4 is started in individuals 
with a serum TSH greater than 10 mIU/L and considered to start in those with a 
serum TSH 4.5–10 mIU/L especially greater than 7 mIU/L, who are younger than 
65 years with increased cardiovascular risk. Patients with persistent mild elevations 
in TSH with positive serum thyroid peroxidase (TPO) antibodies and ultrasound 
findings consistent with autoimmune thyroiditis could be considered for treatment. 
These guidelines recommends against treatment of elderly (65–80 years) patients 
with TSH levels less than 10 mIU/L [13].
The British Thyroid Association recommends starting treatment in patients with 
positive antibodies or serum TSH >10 mU/L. The guideline advise to start with LT4 
doses between 50 and 125 mcg/day. Treatment should aim for TSH levels within the 
normal reference range. Older individuals or with cardiac disease, require smaller 
starting doses to avoid inducing cardiac ischaemia. Combined therapy with LT4 and 
liothyronine (LT3) is not routinely recommended [14].
The American Association of Clinical Endocrinology recommends starting 
treatment with LT4 in patients with TSH > 10 mIU / L or those with symptoms, 
cardiovascular risk factors or positive TPO antibody. The goal of LT4 therapy is 
to normalize TSH. The starting dose of LT4 is 1.5 mcg/kg in the absence of car-
diovascular disease. In patients with cardiovascular disease, the starting dose of 
LT4 is 25 mcg and is up-titrated as needed [12]. The American Endocrine Society 
recommends against routine treatment of SCH patients with serum TSH levels of 
4.5–10 mU/liter, but indicated that treatment was reasonable for patients with TSH 
levels greater than 10 mU/liter [15].
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The American Association of Clinical Endocrinology recommends starting 
treatment with LT4 in patients with TSH > 10 mIU / L or those with symptoms, 
cardiovascular risk factors or positive TPO antibody. The goal of LT4 therapy is to 
normalize TSH. The starting dose of LT4 is 1.5 mcg/kg in the absence of cardiovas-
cular disease. In patients with cardiovascular disease, the starting dose of LT4 is 25 
mcg and is up-titrated as needed [12].
5. Myxoedema coma
Myxedema coma is the most extreme, life-threatening expression of severe 
hypothyroidism. Usual precipitating factors are discontinuation of therapy, infec-
tions and exposure to cold. Its clinical manifestations include hypothermia, respira-
tory depression, cardiovascular instability and altered mental status [1]. According 
to the American Thyroid Association guidelines, patients with myxedema coma 
should first receive empiric glucocorticoid coverage with intravenous glucocorti-
coid administration (at appropriate doses for the stressed state). These guidelines 
recommends a daily intravenous dose of 200 to 400 mcg of LT4, with lower doses 
given for patients who are of smaller stature, older, or who have a history of coro-
nary disease or arrhythmia. Subsequently, daily dosing of 1.6 mcg/kg/day reduced 
to 75%, should be given.
Additional administration of intravenous T3 in a loading dose of 5–20 μg, 
followed by a maintenance dose of 2.5 to 10 mcg every 8 hours is recommended 
[1, 16–18]. For the Latin American Thyroid Society guidelines, LT4 replacement is 
the backbone of myxedema coma therapy. The daily starting dose is 300–500 μg/
day followed by maintenance dose 50–100 μg/day. T3 can be added to therapy at 
10–20 mg bolus followed by 10 μg every 4–6 hours [19]. The necessity of intrave-
nous LT4 replacement is apparent, but administering LT4 alone or with a combina-
tion of LT4 and LT3 remains controversial [1, 16–18]. Carter et al. [20] prouved that 
combinated treatment with LT3 and LT4 are more beneficial than LT4 monotherapy 
to improve symptoms and to reverse the biochemical abnormalities in patients with 
myxedema coma. At the same Ono et al. [21] showed that patients receiving LT4 
combined with LT3 had a lower mortality rate than those who received LT4 alone. 
T3 is an active hormone in the body with an immediate onset of action, whereas LT4 
has a slow onset of action with relatively few adverse events. Also T3 affinity for the 
nuclear receptor is 10- to 20- fold higher than that of T4 and it reaches a peak level 
in 2–4 h after administration [22]. The beneficial effect of this combined treatment 
on neuropsychiatric symptoms has been confirmed because of the capacity of T3 to 
cross the blood brain barrier [23].
6. Pregnancy
6.1 Treatment of overt hypothyroidism in pregnancy
Women with overt hypothyroidism who contemplate pregnancy must first 
normalize TSH and thyroid hormone levels. LT4 is the first choice of treatment. 
American Thyroid Association guidelines specifies a goal of TSH less than 2·5 
mIU/L in women planning to become pregnant [24]. Women with a previous 
diagnosis of hypothyroidism, should checked their serum TSH concentration and 
increased LT4 dose made as soon as possible after pregnancy is confirmed [25]. The 




is 25–50% higher than levels used in the general population (1.6–1.8 μg/kg body 
weight) [26].
Once pregnant, women should increased the dose of LT4 by about 30–50%, 
beginning in the first 4–8 weeks of gestation and gradually increasing the dose 
through 16–20 weeks of gestation [27]. After initiation of therapy, thyroid function 
should be retested within 30–40 days, and then every 4–6 weeks. Maternal TSH 
concentrations should be maintained between 0·1–2·5 mIU/L in the first trimester, 
0·2–3·0 mIU/L in the second, and 0·3–3·0 mIU/L in the third [27, 28].
6.2 Treatment of SCH in pregnancy
According to the American Thyroid Association guidelines, TSH levels should be 
keept below 2.5 mU/L and 3.0 mU/L in the first and second/third trimesters, respec-
tively [28]. Autoantibodies to TPO should be mesured in women with SCH, since TPO 
positivity acts in synergy with SCH and it is an independent risk factor for pregnancy 
outcomes [29–31]. The rise of maternal TSH level increase the risk of miscarriage. 
This risk becomes even greater at a TSH level > 2.5 mU/L, accompanied by TPO posi-
tivity [24]. Pregnant women with SCH have a higher risk of several side effects such as 
pregnancy loss and premature birth [32]. In women receiving LT4 treatment for SCH, 
the risk of miscarriage in early pregnancy increases at a TSH level > 4.5 mU/L.
It was showed that LT4 treatment is capable to reduce the rate of pregnancy loss 
in TPO positive euthyroid women, therefore starting treatment with low doses of 
LT4 may be considered in TPO positive women with a history of recurrent preg-
nancy loss [33, 34]. Starting doses of LT4 were based on TSH levels, either 1 μg/kg/ 
day (TSH 1.5–2.5 mU/L) or 0.5 μg/kg/day (TSH 0.5–1.5 mU/L), raising or lowering 
amounts by 0.5 μg/day at TSH levels >3 mU/L or < 0.5 mU/L, respectively [34].
7. Coronary artery disease
If untreated, hypothyroidism in patients with coronary heart disease might lead 
to ventricular arrhythmias, congestive heart failure or acute myocardial infarction.
Therefore, patients with coronary artery disease and hypothyroidism should be 
treated cautiously with thyroid hormone replacement [35]. Therapy is performed 
with the administration of LT4,that induced significant improvement in myocardial 
function, cardiac pump function and resting cardiac output [36]. However, in 
subjects with an already compromised myocardial blood supply due to coronary 
atherosclerosis, LT4 treatment may lead to anginal symptoms. A previous study 
showed that 2% among 1503 hypothyroid subjects presented new onset angina dur-
ing LT4 therapy [37]. The recommended initial therapeutic dose for patients with 
pre-existing angina is 25 mg / day or even less and it should not be increased faster 
than at 4 week intervals [38].
8. Elderly
The serum TSH levels reference range is 4–5 mIU/L in the elderly patients. The 
hormone replacement with LT4 is the specific therapy for old individuals with 
hypothyroidism [39]. A normal starting dose of LT4 in an elderly subject is around 
1 mg/kg/day, which is maintained for 4–6 weeks [40]. Dosage adjustments are 
guided by the TSH response and the clinical state, with emphasis on possible cardiac 
adverse effects [38]. Some experts recommended to increase the dosage by 25 μg in 
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accordance with the patient’s complaints [41]. While this therapeutic dose should 
be reduced of about 50 μg/day, or 25 μg/day when the patient was underweight or 
developed cardiovascular disease [39].
Hormone replacement with LT4 in patients with hypothyroidism requires specific 
therapy. LT4 is available in the form of tablets at various doses, but also in liquid form 
as an oral solution, thus enabling a customized dose titration [41]. The European 
Thyroid Association recommends treatment in patients above 70 years old who have 
a TSH >10 mUI/L and signs and/or symptoms of hypothyroidism [11]. However, the 
LT4 dose needs to be tailored, aiming for a TSH level between 4 and 10 mIU/L, while 
the patient’s health condition and the potential presence of dyslipidemia and other 
metabolic derangements should be considered [42].
Likewise, van den Beld et al. [43] showed that low serum FT4 levels are associated 
with a longer 4-year survival, reflecting a possible adaptive mechanism to prevent 
excessive catabolism in the elderly. Hypothyroidism is prevalent among the elderly 
population, that’s why efforts should be made to maintain optimal thyroid function 
with individualized treatment based on severity and comorbidities [43].
9. COVID-19
Hypothyroidism is not a risk factor associated with worse outcomes in COVID-
19 positive patients, therefore no particular changes or consultations are envisaged 
relating to the diagnosis and treatment of hypothyroidism during the COVID-19 
crisis [44]. It is recommended to pursue the same form, frequence and dosage 
of thyroid hormone replacement therapy. No particular therapeutic dosage was 
addressed. Regular blood test monitoring may be difficult, but when patients on 
thyroid hormone replacement feel significantly unwell or if there are significant 
weight changes, thyroid function testing with measurement of serum TSH and free 
thyroxine, is recommended to adjust medication if needed [45].
10. Obesity
LT4 is the treatment of patients developed SCH associated with hyperlipidae. T3 
can be added for patients with adequately substituted hypothyroidism with obesity 
resistant to a lifestyle intervention or suspected of thyroid hormone conversion 
disorders [46].
An individual approach of treatment is necessary for obese patients with higher 
TSH levels. The clinical condition of elevated TSH without symptoms, thyroid 
antibodies, goiter, or associated thyroidal illness, was defined as obesity-associated 
hyperthyrotropinemia. The efficacy of thyroid hormone therapy in obese subjects 
with hyperthyrotropinemia has not yet been evaluated [47]. LT4 treatment of obese 
with hyperthyrotropinemia were performed only in children demonstrating that 
the increase TSH levels causes impaired glucose metabolism and dyslipidemia [48].
However, no evidence regarding a favorable effect of LT4 treatment on body 
weight in obese subjects with TSH < 10 mU/L and normal free thyroxine level 
has been demonstrated, so such treatment is not recommended. In such subjects 
dietary-behavioral intervention contributed to weight loss irrespective of LT4 use. 
However, in normal-weight patients with hypothyroidism LT4 treatment is an effec-
tive strategy to decrease total and LDL cholesterol, this effect is more pronounced in 
patients with TSH > 10 mU/L [11]. Obese individuals with isolated hyperthyrotro-
pinemia without symptoms or other signs of thyroid disease should not be treated 




The role of thyroid hormone in treating obesity was confirmed. So that T3 
and T4 administration at varying doses and durations has been shown to enhance 
weight loss in obese euthyroid subjects [49]. Such therapy increased fat loss 
without decreasing skeletal muscle mass and strength or inducing cardiac dys-
function [50]. However, a systematic review by Kaptein et al. [51] describing the 
effects of T3 or T3/T4 treatment on weight loss in euthyroid individuals during 
caloric deprivation showed that T3 is associated with decreases in serum T4 
concentrations, indicating pituitary suppression of TSH, resulting in subclinical 
hyperthyroidism.
11. Adrenal insufficiency
Glucocorticoid deficiency can accompany hypothyroidism and if it is not 
detected, it may be exacerbated by thyroid hormone replacement, raising the 
risk of adrenal crisis that can be fatal. The signs and symptoms of coexisting 
adrenal insufficiency are manifold and can be summarized as hypoglycemia, 
anemia, nausea, vomiting, alopecia areata, weight loss, abdominal pain, hypo-
tension and hyperpigmentation [52]. If so, it is important to start with replacing 
glucocorticoids first before starting LT4 and then approaching LT4 replacement 
5–7 days later. Starting by LT4 therapy can contribuate to an increased metabo-
lism which raise demand of cortisol, leading then to an increased risk of an 
adrenal crisis [38, 53].
Not to be confused, the modest increase of serum TSH levels in cases of 
untreated adrenal insufficiency, might return to normal without for thyroid hor-
mone replacement but only by the correct hydrocortisone replacement treatment. 
The diurnal variation in TSH levels is influenced by cortisol, it manifests higher 
concentrations at night and lower in the morning, which explains the increase in 
TSH levels in untreated adrenal insufficiency [54].
12. Differentiated thyroid cancer
Differentiated thyroid cancer should be treated with an appropriate expertise in 
order to ensure an optimal long-term treatment quality. The therapeutic approach is 
individualized and risk-adapted. Surgery and radioiodine therapy followed by LT4 
substitution is the established therapeutic procedures. For widely invasive follicular 
thyroid carcinomas and follicular thyroid carcinoma with vascular infiltration, 
thyreoidectomy is recommended. Radioiodine therapy has been established for 
more than 60 years, consisted on systemic administration of radioiodine (I-131) 
to irradiate thyroid remnants as well as non-resectable or incompletely resected 
differentiated thyroid cancer.
The benefit of I-131 therapy was confirmed in individuals with differentiated 
thyroid cancer at high risk for recurrence, however in subjects with very low-risk 
differentiated thyroid cancer the positive effect of radioiodine on tumor-free and 
overall survival has not been proven [55]. Patients who undergone thyroidectomy for 
differentiated thyroid cancer, with or without additional treatment with I-131, need 
to take LT4 not only for treatment of hypothyroidism but also to minimize potential 
TSH stimulation of tumor growth [56]. The recommended levels of thyroid-
stimulating hormone (mIU/L) targets in patients with differentiated thyroid cancer 
by American Thyroid Association are;<0.1 for high and intermediate risk (initial 
therapy) and persistent disease, 0.1–0.5 for high-risk disease free (follow-up) and 
low risk (initial therapy) and 0.3–2.0 for low-risk disease free (follow-up) [57].
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13. Anemia
Anemia seems to be associated with thyroid dysfunction particularly hypothy-
roidism. Anemia was found in 65% of children and adolescents with hypothyroid-
ism [58]. At the same, 10% of the individuals with thyroiditis manifested anemia. 
These patients may be particularly sensitive  at the beginning of LT4 replacement 
therapy [59]. Lack of stimulation of erythroid colony development by thyroid hor-
mones, reduction in oxygen distribution to tissues and diminution of erythropoi-
etin level in the absence of thyroid hormones leads to anemia [60]. The correction 
of hypothyroidism promotes an adequate therapeutic response to iron salts. Iron 
may interfere with the absorption of the thyroid hormone, that’s why LT4 should be 
taken at least four hours apart from the iron intake [52].
14. LT4 intolerance
A sympathetic hyperactivity may appear during the first hours after the LT4 
administration manifested by precordialgia or palpitations. This condition requires 
starting with very low doses of LT4 that should be increased gradually, and reach-
ing normal TSH may took several months. The sympathetic hyperactivity may be 
attributable to the presence of uncorrected iron-deficiency anemia that worsens by 
the use of thyroid hormone. The anemia should be corrected and thyroid hormone 
therapy should be stoped temporarily and then restarted at low doses. Occasionally, 
beta blockers can be used in these cases to control the symptoms during the first few 
weeks of thyroid replacement treatment [59, 61].
15. Conclusion
Hypothyroidism is a common disorder, diagnosed by the measurement of blood 
levels of thyroid hormones. In the face of this challenge, efforts should be made to 
maintain optimal thyroid function. Therapy of choise is the administration of LT4. 
Treatment should be individualized in accordance with the subject’s age, weight, 
severity and comorbidities. Special situations can coexist such as adrenal insuf-
ficiency, pregnant women, elderly patients and patients with differentiated thyroid 
cancer, needing special considerations to ensure the patient’s welfare and prevent 
therapeutic complications. Under- or over-treatment is common in clinical practice 
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